|
| |
|
|
A look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and the health policy trends in Canada from InnomarLive.
|
|
|
|
|
|
When HTA Decisions Occur, We Keep You Informed.
|
|
Xcenda’s HTA Decision Map makes it easy to stay informed. Find out how new products are faring with HTA authorities in:
- Australia
- Canada
- France
- Germany
- United Kingdom
|
|
|
|
|
|
|
|
|
|
“For the reasons described previously, it is critical that information provided by firms about their unapproved products and about unapproved uses of approved/cleared products be truthful and non-misleading.”
|
|
Comments regarding requests from payors to receive information from firms about medical products that are not yet approved/cleared by FDA for any use, and about unapproved uses of approved/cleared medical products, so they can plan for and make coverage and reimbursement decisions far in advance of the effective date of such decisions.
|
|
|
|
|
|
|
The UK has established a £2.5 billion ($3.6 billion) patient capital program to help support the development of British biotechs and high-growth companies into standalone operations. The objective of the fund is to support the development of these firms that would otherwise sell out to international firms.
Source: U.K. creates £2.5B investment program to help startups grow
|
|
|
|
|
|
|
|
| GLOBAL REACH. LOCAL EXPERTISE. |
|
 |
Gain Global Market Access Insights. Let Our Experts Help.
|
|
Need insights for new geographic markets? Have pressing market access questions that could use the insight of local experts? Then partner with Xcenda and our Global Market Access Network (GMAN) advisors while you’re at ISPOR’s 21st Annual European Congress in Barcelona, Spain. Gain local insights on pricing, reimbursement, and access from this team of global experts.
|
 |
|
|
|
|
|
|
 |
|
For more than 2 decades, companies have turned to Xcenda’s leading team of value experts, transforming evidence and market intelligence into effective global market access strategies and solutions. Founded in the application of health outcomes and reimbursement, it’s our goal to help prove the inherent worth of client products and services, maximize patient access, and enhance overall brand performance.
Explore our solutions >
|
|
|
|
|
 |
|
|
Subscribe to the newsletter written specifically by and for Global HEOR and Market Access professionals.
|
|
|
|
| EDITORS AND CONTRIBUTING AUTHORS |
|
 |
EDITORIAL BOARD:
Josep Darba, PhD
Professor | Department of Economics | University of Barcelona
George Papadopoulos, BSc(Hons), GradDipEpi
President | Emerald Corporate Group
Ken Redekop, BSc, MPH, PhD
Visiting Associate Professor | National University of Singapore
Eldon Spackman, BA, MA, PhD
Co-Director | Institute for Public Health | University of Calgary
Keith Tolley
Director | Tolley Health Economics
Thomas Mittendorf, MSc, PhD
Managing Director | Xcenda GmbH
Michael Eaddy, PharmD, PhD
Vice President, Scientific Consulting | Xcenda
Jay Jackson, PharmD, MPH
Senior Vice President, Consulting Services | Xcenda
CONTRIBUTING AUTHORS:
Chelsey Campbell, PharmD, MBA, MS | David Campbell, PharmD, MS | Martine Etschmaier, MPH | Minh Luu, MBBS | Kristen Migliaccio-Walle, BS | Roberta Wood, BSc, MBA
PRODUCTION:
Ellen Olson | Laurie Kozbelt | Kylie Matthews
|
|
|
|
|
|
|
|
|
|
|
|
|
Copyright © 2018 AmerisourceBergen
Our address is 1800 Innovation Point, Fort Mill, SC 29715, United States
|
|
 |
|
